Clinical course and outcomes of COVID‐19 in hematopoietic cell transplant patients, a regional report from the Middle East - Summary - MDSpire

Clinical course and outcomes of COVID‐19 in hematopoietic cell transplant patients, a regional report from the Middle East

  • By

  • Riad El Fakih

  • Alfadil Haroon

  • Feras Alfraih

  • Murtadha K. Al-Khabori

  • Mohsen Alzahrani

  • Ahmad Alhuraiji

  • Abdulaziz Hamadah

  • Naif I. AlJohani

  • Bader Alahmari

  • Mohammed F. Essa

  • Ibraheem H. Motabi

  • Imran K. Tailor

  • Reem S. Almaghrabi

  • Khalil Al-Farsi

  • Ibraheem Abosoudah

  • Mouhab Ayas

  • Tusneem A. Elhassan

  • Ashraf M. Suhebeh

  • Syed Osman Ahmed

  • Saud Alhayli

  • Panayotis Kaloyannidis

  • Ahmad Alsaeed

  • Khalid Al Anezi

  • Sameer Alamoudi

  • Moussab Damlaj

  • Hani Al Hashmi

  • Mahmoud Aljurf

  • April 27, 2021

  • 0 min

Share

Objective:

To describe the outcomes and severity of COVID-19 in post-hematopoietic cell transplant (HCT) patients and analyze the impact of various risk factors, including age, sex, and comorbidities, on disease severity.

Key Findings:
  • Median age of patients was 35 years, with a median time from transplant to COVID-19 of 14.9 months.
  • 42% of patients were female, and 48% had prior comorbidities.
  • 86% of patients exhibited symptoms, with fever (56%) and cough (41%) being the most common.
  • 68% of patients had abnormal chest X-ray findings.
  • 52% of patients received COVID-19 directed therapies, indicating a significant treatment response.
Interpretation:

HCT patients are at significant risk for severe COVID-19, with a high rate of symptoms and abnormal clinical findings upon diagnosis, necessitating tailored clinical management.

Limitations:
  • Retrospective design may introduce bias, particularly in data collection.
  • Limited generalizability due to the specific regional focus and small sample size.
Conclusion:

COVID-19 poses a severe risk to HCT patients, highlighting the need for targeted management strategies, such as enhanced monitoring and early intervention in this vulnerable population.

Original Source(s)

Clinical course and outcomes of COVID‐19 in hematopoietic cell transplant patients, a regional report from the Middle East

  • by Riad El Fakih, Alfadil Haroon, Feras Alfraih, Murtadha K. Al-Khabori, Mohsen Alzahrani, Ahmad Alhuraiji, Abdulaziz Hamadah, Naif I. AlJohani, Bader Alahmari, Mohammed F. Essa, Ibraheem H. Motabi, Imran K. Tailor, Reem S. Almaghrabi, Khalil Al-Farsi, Ibraheem Abosoudah, Mouhab Ayas, Tusneem A. Elhassan, Ashraf M. Suhebeh, Syed Osman Ahmed, Saud Alhayli, Panayotis Kaloyannidis, Ahmad Alsaeed, Khalid Al Anezi, Sameer Alamoudi, Moussab Damlaj, Hani Al Hashmi, Mahmoud Aljurf

  • April 27, 2021

Related Content

Case Report: Beyond conventional diagnostics: mNGS support in a complex immunocompromised patient diagnosis

Prospective systematic classification of causes of death in the course of multiple myeloma

The Care Continuum of Patients With Influenza in the Post–COVID-19 Era: A Position Paper